ARCHIVES

Interim Funding: Noncompeting Renewals Reduced By 4 Percent, Competing Current Plus 7 Percent

This article is from The Cancer Letter archive.

Vol. 08 No. 02 | January 8, 1982

Download PDF Visit The Full Archive

Related Articles

“Official Chronology” Of Gall/Montagnier Finding Agreed On; Royalties to Fund AIDS research

April 10, 1987

Capitated Oncology Becomes Marketplace Reality Wit Plan By Companies

January 14, 1994

Rosenberg’s Adoptive Immunotherapy Update

December 6, 1985

NCI Considers Seeking New Study Section For Clinical Research, Or Expansion Of E2

November 23, 1990

FDA Approves Gemzar For Ovarian Cancer, Contradicting ODAC Recommendation; Continues Agency Trend to Recognize Progression-Free Survival As An Endpoint.

July 21, 2006

Cervical Screening Should Emphasize Older Women, ASP Members Told

March 14, 1986